However, it could be worth evaluating a triple antiplatelet therapy in higher risk patients, in a randomized fashion, and with a much larger sample size. Joint Utilisation of Medications to Block ...

No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

for dual antiplatelet therapy, 1.83 (95% CI, 1.72–1.96) for warfarin plus aspirin, 3.08 (95% CI, 2.32–3.91) for warfarin plus clopidogrel, and 3.70 (95% CI, 2.89–4.76) for triple therapy.